In a significant portfolio shift, Harry Burn's Sound Shore Management completely sold off its position in Teva Pharmaceutical Industries (TEVA) during the third quarter of 2026. According to a recent 13F filing with the SEC, the firm liquidated all 3.80 million shares it held, which were valued at approximately $128.90 million at the end of June. This disclosure, filed on November 6, 2026, reflects the firm's holdings as of September 30, 2026, and does not represent a real-time trade.

The exit occurred as Teva reported third-quarter earnings that beat analyst estimates and raised its full-year revenue guidance. The company has been transitioning from a generics-focused business to a biopharmaceutical company, with its innovative drugs showing strong sales growth. Despite this positive news, Sound Shore, a major investor, has now fully divested from the pharmaceutical company.